NY-ACETO
Aceto, the supplier of choice for life sciences and advanced technology specialty ingredients, today announced the acquisition of Biotron Laboratories and Talus Mineral Company (affiliated entities collectively referred to as Biotron herein), leading manufacturers of specialty ingredients for the nutritional supplements industry. The Biotron acquisition expands Aceto’s existing nutraceuticals business and further strengthens its life science sector presence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220302005041/en/
For more than 40 years, Salt Lake City-based Biotron has been a leading manufacturer of premium specialty minerals, trace elements and other solutions for the nutritional supplements industry. It is well known for its proprietary technology for producing mineral chelates, which are widely used in nutritional supplements. Biotron’s amino-acid based chelation process results in superior quality minerals and trace elements with greater bioavailability and enhanced user tolerance. Biotron has strong research and development capabilities and two manufacturing facilities located near its Utah headquarters.
“Biotron is the latest of our recent acquisitions of exceptional life-science specialty manufacturers, and they bring important new capabilities to Aceto,” said Gilles Cottier, Chief Executive Officer of Aceto. “Over four decades they have built a strong reputation in the nutritional supplements industry for their unique mineral chelation process, high-quality trace elements and other specialty ingredients. They are known for their focus on R&D and ability to work with customers on a variety of custom and specialty orders. Biotron is a great addition to our already-substantial nutraceuticals business, with a complementary portfolio of customers. We are delighted to welcome them to the growing Aceto family of life science specialty manufacturers and suppliers.”
Gameil T. Fouad, PhD, President of Biotron Laboratories, commented, “At Biotron we are very proud of what our team has accomplished over the past 40 years. Our scientist-founder, my father, imbued Biotron with a passion for science and quality that has characterized the company throughout our decades of growth. Aceto shares these principles and joining forces is the logical next step in enabling the continued growth and evolution of our business.” CEO of Talus Mineral Company, Dave Johnson, added, “As part of the Aceto family, we are excited to bring our unique capabilities to serve more clients globally as well as continuing to deepen our relationships with existing customers and suppliers. We look forward to investing further in our site capabilities and continuing to offer unparalleled customer service to all our clients.”
Biotron Laboratories is certified to the NSF/GMP standard and is registered as an FDA food facility.
G2 Capital Advisors, LLC and Foley & Lardner, LLP advised Biotron Laboratories and Talus Mineral Company on the transaction. Ulmer & Berne, LLP advised Aceto. Financial terms of the transaction were not disclosed.
About Aceto
Aceto is the supplier of choice for differentiated specialty materials in the life sciences and advanced technology end markets. With business operations in 10 countries, Aceto manufactures and supplies more than 3,000 chemical compounds used principally by the pharmaceutical, nutraceutical, agricultural, and specialty chemical industries. In the last two years, Aceto has made seven acquisitions, including Biotron, which has expanded its manufacturing, R&D, and portfolio offerings, transforming the company into a worldwide supplier of critical ingredients with a robust manufacturing footprint. Aceto’s global operations, including a significant presence on the ground in China, India, Europe and North America, enable the company’s deep worldwide sourcing and regulatory capabilities. Aceto is well positioned to innovate new solutions, ensure quality and customize products to meet customers’ specific needs. Its expanded capabilities and decades of global sourcing expertise are especially valuable now that supply chain management is a critical strategic issue for companies worldwide. For more information visit aceto.com .
About Biotron Laboratories and Talus Mineral Company (Collectively “Biotron”)
Biotron Laboratories and Talus Mineral Company (“Biotron”), founded in 1979 and 2014, respectively, are affiliated entities that in partnership manufacture and supply leading specialty minerals and nutritional ingredients to global markets. Biotron provides clients excellent customer service, agile processing capabilities, and proprietary production methods to deliver the highest quality ingredients with speed and certainty. The company provides over 250 products, including mineral complexes, custom blends, fortified blends, and chelates, which include magnesium-based, zinc-based, calcium-based and iron-based products. Products include halal, kosher, vegan and organic certified options. Biotron’s manufacturing operations are located in Centerville, Utah and Ogden, Utah. For more information visit https://www.biotronlabs.com/index.php and http://www.talusminerals.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street Announces Upcoming 2025 Investor Conference Schedule15.5.2025 22:51:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Michael L. Perica, chief financial officer, and Dean Pohl, vice president, treasurer and investor relations, will be presenting and meeting with investors one-on-one and in small group meetings at the following conferences: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515374696/en/ Rimini Street Announces Upcoming 2025 Investor Conference Schedule May 28, 2025: Craig-Hallum 22nd Annual Institutional Investor Conference, Minneapolis May 29, 2025: TD Cowen 53rd Annual TMT Conference, New York City Fireside Chat: 1:15 pm Eastern, webcast link June 24-26, 2025: Roth 15th Annual London Conference, London To schedule a meeting please contact your salesperson or Rimini Street Investor Relations at IR@rimin
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States15.5.2025 20:30:00 CEST | Press release
Zynyz® (retifanlimab-dlwr), a PD-1 inhibitor, is now approved for the treatment of advanced squamous cell carcinoma of the anal canal (SCAC) in combination with chemotherapy and as a monotherapyPatients with SCAC treated with Zynyz achieved a statistically significant improvement in progression-free survival and improvement in overall survival Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. Thi
DDC Announces Record 2024 Growth and Strategic Bitcoin Reserve Initiative in Shareholder Letter by Founder & CEO Norma Chu15.5.2025 20:23:00 CEST | Press release
DDC Enterprise Ltd. (NYSEAM: DDC), today released its 2024 full year results alongside a Shareholder Letter from Founder, Chairwoman, and CEO Norma Chu, underscoring the company’s positive financial performance and unveiling a pioneering Bitcoin accumulation strategy poised to redefine long-term value creation. To Our Valued Shareholders, 2024 was a year of transformative growth and strategic milestones for DDC. I am thrilled to share that we not only met our financial forecasts but exceeded expectations, delivering strong performance across key metrics while laying the groundwork for an even more exciting future. As we enter 2025, our momentum is accelerating, driven by disciplined execution and a bold new chapter in our corporate strategy. 2024 Financial & Operational HighlightsRevenue Growth: USD 37.4 million, a 33% year-over-year increase, propelled by the strategic acquisition of U.S. brands and sustained resilience in our core China operations. Margin Expansion: Gross profit marg
Ras Al Khaimah’s Strong Economic and Investment Environment Validated by Fitch Affirmation of ‘A+’ Credit Rating, With Stable Outlook15.5.2025 20:18:00 CEST | Press release
The positive rating reflects the Emirate’s strong long-term growth prospects and ongoing economic diversification Ras Al Khaimah’s strategic approach to sustainable, cross-sector growth and strong economic and investment environment has been validated by international credit rating agency Fitch, which reaffirmed the rating at ‘A+’ with a stable outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515907689/en/ Ras Al Khaimah’s strong economic and investment environment validated by Fitch affirmation of ‘A+’ credit rating, with Stable Outlook (Photo: AETOSWire) Ras Al Khaimah Government welcomed the announcement as an endorsement of the Emirate’s resilient and expanding economy, sound fiscal management and the clear vision and unwavering commitment of its leadership to sustainable, long-term development and growth. The Emirate’s landmark tourism projects, including a major integrated resort, luxury hotels and world-clas
Cessna Citation CJ4 Gen3 Flight Test Program Advances Through Milestones as Second Test Article Takes Flight15.5.2025 20:00:00 CEST | Press release
Textron Aviation today announced a major program milestone for the Cessna Citation CJ4 Gen3 flight test program with the successful first flight of a second test article — P1. Testing on the P1 aircraft will focus on avionics, human factors and interiors. The Citation CJ4 Gen3 business jet is designed to keep pilots a step ahead in the cockpit by offering the next-generation Garmin G3000 PRIME avionics along with the most standard features in its class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515438856/en/ Cessna Citation CJ4 Gen3 flight test program advances through milestones as second test article takes flight. (Photo Credit: Textron Aviation) The Cessna Citation CJ4 Gen3 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “This achievement continues the forward momentum of the CJ4 Gen3 program and reflects the dedication and expertise of our team in designing, certifying an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom